Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial.
Lists
Only you see this
Abstract
6007 Background: There are no well-established first-line chemotherapy regimens for recurrent or metastatic (R/M) NPC. Several small phase II trials suggest that GP has promising efficacy and acceptable toxicities. This phase III trial compared the efficacy and safety of GP versus FP as first-line therapy for patients with R/M NPC. This trial has been selected as “Trials in Progress” and presented in the poseter session in 2015 ASCO meeting (Abstract No. TPS6098). Methods: Eligible patients were randomized in 1:1 ratio to receive either GP (gemcitabine 1 g/m2 on days 1, 8, cisplatin 80 mg/m2 on day 1, q3w) or FP regimens (5-FU 4 g/m2 CIV over 96 hours, cisplatin 80 mg/m2 on day 1, q3w) for up to 6 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), safety and quality of life. Results: From February 2012 to October 2015, 362 patients from 22 institutions were randomly assigned to GP (n = 181) or FP (n = 181) group. Baseline characteristics were similar between both arms. The median PFS was 6.83 months in the GP group and 5.70 months in the FP group (HR = 0.57; 95% CI [0.46-0.71]; p < 0.0001). At 1 year, the PFS rate was 21% (95% CI, 18 to 24) with GP versus 6% (95% CI, 4 to 8) with FP. This effect was consistent for the best ORR (GP 68.3% versus FP 47.1%; p = 0.0001). The most common grade ≥ 3 related adverse events (AEs) were leukopenia (21.1%) and thrombocytopenia (11.1%) with GP and mucositis (12.9%) with FP. Treatment discontinuation due to related AEs was similar between both arms (GP 3.9% versus FP 5.5%; p = 0.458). Conclusions: First-line GP significantly improved PFS compared to FP in R/M NPC. Consistent benefit was seen with ORR. AEs were manageable with similar low discontinuation rates in both arms. Updated and OS data will be presented at ASCO meeting. Clinical trial information: NCT01528618.
BibTeX
@article{zhang2016gemcitabine,
author = {Li Zhang and Gengsheng Yu and Jun Jia and Peijian Peng and Qing Lin and Xuping Xi and Jiewen Peng and Mingjun Xu and Dongping Chen and Xiaojun Lu and Rensheng Wang and Xiaolong Cao and Xiaozhong Chen and Zhixiong Lin and Jian Xiong and Qin Lin and Conghua Xie and Zhihua Li and Chong Zhao and Shaodong Hong},
title = {{Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial.}},
journal = {Journal of Clinical Oncology},
year = {2016},
doi = {10.1200/jco.2016.34.15\_suppl.6007},
}Loading related content...